Poolbeg Pharma plc

We have signed an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate for #Behçets Disease. The topical muco-adherent formulation of Pentoxifylline to treat oral ulcers has FDA Fast Track and Orphan Designation, positive Phase 2 data, and is positioned for potential 505(b)(2) regulatory pathway in the U.S. that can result in a much less expensive and much faster route to approval and commercialisation. There is a clear unmet medical need for an effective treatment for this rare disease, which currently has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impacts essential functions like eating, drinking and speaking. Read full announcement here: https://lnkd.in/ePAg63sW #POLB #Behçets #BehçetsDisease #raredisease #orphan

There are >7,000 rare diseases affecting patients around the world, but due to the low prevalence of these diseases, diagnosis can be difficult and treatments are often unavailable or inadequate. 🎯 There is a strong need for more scientific research to find solutions for these diseases and provide support to the >300 million people living with a #raredisease worldwide. Learn more: https://lnkd.in/emc49iPd

Unfortunately, there's no definitive test that can be used to diagnose Behçet's disease. A patient will have to endure several tests to check for signs of the condition, or to help rule out other causes, such as: 💉Blood tests 💧Urine tests 🩺Scans, such as X-rays, a CT scan or an MRI scan 🔪Skin biopsy ☑️Pathergy test Current guidelines state a diagnosis of Behçet's disease can usually be confidently made if a patient has experienced at least 3 episodes of mouth ulcers over the past 12 months and have at least 2 of the most common symptoms. Other potential causes also need to be ruled out before the diagnosis is made.

People suffering from #Behçetsdisease can have different #symptoms, however the most common symptom is severe ulcers in the mouth. Slide along to understand the different types of symptoms caused by this rare disease. ⚠️Warning: swipe with caution - graphic medical photos #POLB

Want to know more about Behçet’s disease? Genetic Alliance UK have shared a patients story, providing an overview on the severity of this rare disease, highlighting the importance of the need for a cure and effective treatments. https://lnkd.in/gTTcANZ4 #Behçets #BehçetsDisease #POLB $POLBF

Last week Scrip covered the option Poolbeg Pharma plc signed for an orphan drug candidate for Behçets Disease. Read it here: https://lnkd.in/eayH88ii #raredisease #orphandisease #pharma #POLB #BehçetsDisease

Did you see Poolbeg Pharma plc in UK Investor Magazine? 🚀 "Poolbeg Pharma shares jump after announcing year of progress" 💪 >$10bn market opportunity for POLB 001 🤝 Option agreement for rare disease treatment 💰 Robust cash balance https://lnkd.in/gfnur3-b #POLB #POLBF

In case you missed Tuesday's Investor Meet Company presentation featuring our CEO Jeremy Skillington, PhD, CBO David Allmond and the CEO of Silk Road Therapeutics Timothy Cote, you can now catch up with the full recording here: https://lnkd.in/g4EW7R7M #POLB #Presentation

Our CEO Jeremy Skillington, PhD caught up with John Hughman at Vox Markets to discuss: 🔦 Operational & financial highlights for 2023 🤝 Rare disease candidate option agreement 🚀 What's to come in 2024 Watch full interview: https://lnkd.in/gA2uYdpS #POLB #Results

Our Chief Legal Officer John McEvoy speaks with Stephen Gunnion at Proactive to discuss this morning's announcement: 👁️ Overview of granted patent from the US Patent Office 🤝 Enhancing the value and attractiveness of POLB 001 for potential partners 🌱 Why building a strong intellectual property portfolio is so important in pharma https://lnkd.in/gq9hv9fi #POLB #POLBF #Patent #USPatent